0
0
Washington, D.C. — July 31, 2025:
President Donald Trump ordered the removal of the U.S. government’s top vaccine regulator this week, directly overruling the objections of Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration (FDA) Commissioner Marty Makary, according to multiple reports citing senior administration officials.
Dr. Vinay Prasad, the FDA’s chief vaccine regulator and Director of the Center for Biologics Evaluation and Research, abruptly departed his post Tuesday night. POLITICO reported that the decision came after mounting criticism from conservative voices who questioned his alignment with the Trump administration’s agenda. Prasad’s departure follows highly publicized disputes over vaccine policy—including recent controversy involving the gene therapy drug Elevidys, developed by Sarepta Therapeutics, after several patient deaths were linked to its use.
Both Secretary Kennedy Jr. and Commissioner Makary reportedly opposed Prasad’s removal, arguing his expertise was crucial as the administration prepared a new round of Covid-19 vaccine policy decisions ahead of the upcoming fall immunization campaign. However, sources familiar with the matter say President Trump insisted on a change in leadership, believing new direction was needed for the nation’s vaccine approval process.
Health and Human Services declined to say who would replace Dr. Prasad or how the vacancy might affect ongoing vaccine reviews. An HHS spokesperson thanked Prasad “for his service and the many important reforms he was able to achieve at the FDA,” while also noting his decision “not to be a distraction” after intensifying political scrutiny.
Dr. Prasad, who could not be reached for comment, was known for his outspoken criticism of U.S. vaccine mandates during the pandemic and served as a key advisor to Commissioner Makary in efforts to streamline FDA approval pathways. His sudden exit marks the latest in a series of high-level personnel changes within federal health agencies during Trump’s second term, raising concerns within the pharmaceutical industry about the stability and direction of the FDA’s regulatory process.
Disclaimer: This article is for informational purposes only. The details are based on published news reports as of July 31, 2025, and may evolve as more information emerges. It does not constitute official confirmation by the U.S. government or its agencies.
